Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q3 2022 Earnings Presentation

23 slides from Reata Pharmaceuticals's earnings presentation, Nov 8, 2022

  1. Slide 1: 3rd Quarter 2022 Financial Results and Update on Development Programs

    3rd Quarter 2022 Financial Results and Update on Development Programs November 8, 2022 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg

  3. Slide 3: Today's Agenda

    Today’s Agenda Opening Remarks | Warren Huff, CEO Development Update | Colin Meyer, Chief Innovation Officer Commercial Update | Dawn Bir, Chief Commercial Officer Financial & Operational Update | Manmeet Soni, President, COO & CF0 Concluding Remarks | Warren Huff, CEO

  4. Slide 4: Omaveloxolone Program in FA Development Timeline

    Omaveloxolone Program in FA Development Timeline FA: Friedreich’s ataxia, mFARS: modified Friedreich’s ataxia rating scale, NDA: New Drug Application, FDA: United States Food & Drug Administration, PDUFA: Prescription Drug User Fee Act, MAA: Marketing Authorization Application 2Q21 FDA suggests Pre-

  5. Slide 5: Late-Cycle Meeting Agenda and Discussion

    Late-Cycle Meeting Agenda and Discussion Meeting does not address the final regulatory decision for the NDA FDA stated they continue to review the analyses and data included in the recent NDA submissions No request for additional data or analyses No outstanding information requests No current plans

  6. Slide 6: Omaveloxolone MAA Submission in Europe

    Omaveloxolone MAA Submission in Europe EMA: European Medicines Agency Received a positive opinion from the Pediatric Committee on our Pediatric Investigation Plan Received EMA Follow-Up Protocol Assistance feedback regarding our nonclinical and CMC programs Agreed that certain nonclinical studies, i

  7. Slide 7: Update on Bardoxolone Program in Chronic Kidney Disease

    Update on Bardoxolone Program in Chronic Kidney Disease FALCON Phase 3 trial in patients with ADPKD is ongoing International, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial of bardoxolone in patients with ADPKD Primary endpoint: eGFR change from baseline at Week 108 More th

  8. Slide 8: Omaveloxolone in Friedreich's Ataxia

    Omaveloxolone in Friedreich’s Ataxia

  9. Slide 9: MOXIe Part 2: Pivotal Trial of Omaveloxolone in FA

    MOXIe Part 2: Pivotal Trial of Omaveloxolone in FA MOXIe Part 2, one of the largest completed global interventional studies in patients with FA, met mFARS primary endpoint (p=0.014) Improvement observed in all subsections relative to placebo Major subgroups and all analysis populations favored omave

  10. Slide 10: FA Pathophysiology: Frataxin Deficiency Results in Nrf2 Suppression

    FA Pathophysiology: Frataxin Deficiency Results in Nrf2 Suppression that Impairs Mitochondrial Function Doni et al. FASEB J. 2021;35:e21362; Lodi et al. Proc Natl Acad Sci U S A 1999;96:11492-11495; Drinkard et al., Arch Phys Med Rehabil. 2010;91:1044-1050, OCR: Oxygen consumption rate, FARS: Friedr

  11. Slide 11: Mechanism of Action: mFARS Improvements Associated with Induction of Nrf2

    Mechanism of Action: mFARS Improvements Associated with Induction of Nrf2 Petrillo et al. Int J Mol Sci 2019;20:5211; Reata Study Report RTA400-R-2014 Omaveloxolone restores Nrf2 activity and increases mitochondrial function in FA models and patient fibroblasts In MOXIe Part 2, omaveloxolone treatme

  12. Slide 12: Propensity-Matched Analysis: Use of External Natural History Control Group

    Propensity-Matched Analysis: Use of External Natural History Control Group Post hoc analysis comparing the mFARS progression of omaveloxolone-treated patients in MOXIe Extension propensity score-matched to untreated patients in FA-COMS, the largest natural history study of Friedreich’s ataxia Improv

  13. Slide 13: Commercial Update

    Commercial Update

  14. Slide 14: FA Represents a Significant Commercial Opportunity

    FA Represents a Significant Commercial Opportunity 1NIH Friedreich Ataxia Fact Sheet (Accessed 10/2022); 22022 FA Claims analysis; 3Rummey et al. July 2022, Neurology, DOI 10.1212/WNL.0000000000200913, HCP: Health care provider ~4,000 diagnosed U.S. patients No approved FA therapies Engaged, connect

  15. Slide 15: Launch preparation has accelerated with regulatory progress

    Launch preparation has accelerated with regulatory progress Commercial leadership team with > 25 years average experience Commercial hiring and organizational growth initiated Commercial department expected to be ready by PDUFA date Experienced Reata Commercial Team Actively Preparing for Launch Hig

  16. Slide 16: HCPs Treating FA Patients Identified

    HCPs Treating FA Patients Identified At Launch, Reata’s Sales Force will Focus on HCPs with Diagnosed Patients 12022 FA Claims analysis; 2https://curefa.org/network; 3https://www.ataxia.org/neurologists-and-specialty-clinics/ Reata Commercial team of 55-60 employees including the sales force and pay

  17. Slide 17: Patient Access Services and HCP Support

    Patient Access Services and HCP Support Commercial Copay Support Uninsured Services Therapy Adherence Insurance & Access Resource Referrals New Patient Start The Reata REACH Program: Single Point of Contact for Physicians & Patients Patient intake and new patient starts Commercial copay assistance E

  18. Slide 18: Financial & Operational Update

    Financial & Operational Update

  19. Slide 19: Financial Summary

    Financial Summary 1Excludes stock-based compensation expenses; 2Excludes various adjustments, including stock-based compensation expenses, non-cash interest expense from liability related to sale of future royalties; see the next slide for a reconciliation between GAAP and non-GAAP measures. GAAP: G

  20. Slide 20: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures

  21. Slide 21: Concluding Remarks

    Concluding Remarks

  22. Slide 22: Reata at a Glance

    Reata at a Glance NDA for omaveloxolone in FA under review with PDUFA Feb. 28, 2023 Plan to submit MAA for omaveloxolone this year Plan to pursue development of omaveloxolone in additional neurological diseases FALCON Phase 3 trial in ADPKD ongoing with more than 605 patients enrolled AYAME topline

  23. Slide 23: Thank you

    Thank you

Reata Pharmaceuticals — Q3 2022 Earnings Presentation on 6ix